First Analysis analyst Joseph Munda upgraded Anika Therapeutics to Strong Buy from Outperform with a price target of $65, up from $60. The company's acquisitions of Parcus Medical and Arthrosurface make "what has been a somewhat frustrating story for investors more attractive," Munda tells investors in a research note. He believes investors are willing to sacrifice short-term earnings for long-term growth. The recent pullback in shares offers a "compelling opportunity" to initiate a position in the stock or add to an existing positions, says Munda.